BioCryst Pharmaceuticals Inc 8-K Filings

BioCryst Pharmaceuticals plans to discontinue its internal discovery programs and close its Discovery Center of Excellence in Birmingham, Alabama as part of a strategic effort to strengthen its rare disease pipeline.

The company now expects to incur $6.2–$7.5 million in one-time employee termination and severance expenses related to this plan, of which approximately $5.3–$6.6 million are expected to be cash outflows. Additional costs tied to closing the Birmingham facility, including potential contract and lease termination and asset impairment charges, are still being analyzed, and management states it cannot yet estimate these amounts in good faith. The company indicates it will provide updated cost estimates in a future report and highlights that these expectations involve forward-looking statements subject to risks and uncertainties.

BioCryst Pharmaceuticals is shutting down its internal discovery programs and closing its Discovery Center of Excellence in Birmingham, Alabama by the end of 2026, shifting its research strategy toward external innovation to build its rare disease pipeline.

The company now expects full-year 2026 non-GAAP operating expenses of $420–$440 million, lower than prior guidance of $450–$470 million, while reaffirming 2026 revenue guidance for ORLADEYO and total company revenue. BioCryst highlighted two key clinical programs: the Phase 3 ALPHA-ORBIT trial of navenibart in hereditary angioedema, with top-line 6- and 12‑month efficacy data expected in Q3 2027, and BCX17725 in Netherton syndrome, with proof‑of‑concept data expected by year‑end 2026.

The company has also resolved a manufacturing delay for ORLADEYO oral pellets for pediatric patients and expects product availability in early August 2026.

BioCryst Pharmaceuticals, Inc. reported results of its June 11, 2026 annual stockholder meeting and an update to its equity compensation program. Stockholders approved an amended and restated Stock Incentive Plan, increasing the shares available for issuance by 7,000,000 shares.

Three directors — Theresa M. Heggie, Amy E. McKee, M.D., and Jon P. Stonehouse — were elected to terms ending at the 2029 annual meeting. Stockholders also ratified Ernst & Young LLP as independent registered public accountants for 2026 and approved, on a non-binding basis, the company’s executive compensation.

BioCryst Pharmaceuticals reported first quarter 2026 results with strong growth in its core hereditary angioedema franchise but a large accounting loss from an acquisition. ORLADEYO net revenue reached $148.3 million, up 11% year over year, helping drive total revenue of $156.4 million.

The company recorded a GAAP operating loss of $701.6 million, mainly due to a special, non-cash $697.8 million charge for acquired in-process R&D from its Astria Therapeutics acquisition. On a non-GAAP basis, it generated an operating profit of $54.2 million. Cash, cash equivalents, restricted cash and investments totaled $260.8 million at March 31, 2026, or $330.8 million on a pro forma basis including $70 million received after quarter end from licensing European rights to navenibart.

BioCryst entered a European navenibart license with an Irish affiliate of Neopharmed Gentili, adding up to $275 million in potential milestones and tiered royalties of 18%–30%. It reaffirmed 2026 guidance for global ORLADEYO net revenue of $625–$645 million, total revenue of $635–$660 million, and non-GAAP operating expenses of $450–$470 million, while advancing the navenibart pivotal trial and a Phase 1 study of BCX17725.

BioCryst Pharmaceuticals entered a European license agreement granting an Irish affiliate of Neopharmed Gentili exclusive rights to commercialize navenibart for hereditary angioedema. BioCryst will receive $70 million upfront, up to $275 million in future regulatory and sales milestone payments, plus tiered royalties on net sales ranging from 18% to 30%.

Navenibart is an investigational, long-acting plasma kallikrein inhibitor currently in a Phase 3 program in hereditary angioedema, with the program described as on track to support a US regulatory filing by the end of 2027. The company highlights that the deal strengthens its financial position while leveraging Neopharmed Gentili’s existing European rare disease infrastructure.

BioCryst Pharmaceuticals reported a major turnaround in 2025, driven by its hereditary angioedema drug ORLADEYO. Total revenues reached $874.8 million, up from $450.7 million, and operating results swung from a small loss to $341.0 million of operating profit.

ORLADEYO net revenue was $601.8 million, up 38% year over year, or 43% excluding the divested European business. On a non-GAAP basis, total revenue was $592.9 million and operating profit $214.2 million, both sharply higher. Net income was $263.9 million, or $1.21 per diluted share, marking the company’s first full-year profitability.

Strategically, BioCryst sold its European ORLADEYO business, received FDA approval for an ORLADEYO oral pellet formulation for children with HAE, and completed the acquisition of Astria Therapeutics, adding Phase 3 antibody navenibart to its HAE portfolio. For 2026, it reaffirmed ORLADEYO revenue guidance of $625–$645 million and total revenue of $635–$660 million, with non-GAAP operating expenses expected between $450–$470 million.

BioCryst Pharmaceuticals, Inc. completed its previously agreed merger with Astria Therapeutics, Inc. on January 23, 2026. Axel Merger Sub, Inc., a wholly owned subsidiary of BioCryst, merged with and into Astria, and Astria now operates as a wholly owned subsidiary of BioCryst.

The filing also confirms that the appointment of Jill C. Milne, Ph.D. to BioCryst’s board of directors became effective on the merger closing date after conditions in the merger agreement were satisfied. On January 20, 2026, the board further appointed Dr. Milne to the Compensation Committee and the Science Committee, effective as of the closing date.

BioCryst Pharmaceuticals entered into a new Loan Agreement on January 23, 2026 providing $400 million of initial term loans to help fund its acquisition of Astria Therapeutics and related costs, as well as for working capital and general corporate purposes. The term loans mature on January 23, 2031 and require quarterly interest-only payments, with all principal due at maturity.

The loans bear interest at three-month SOFR, with a floor of 1.75%, plus 4.50% per year, and BioCryst may pay up to 200 basis points of interest in kind until the second anniversary of closing, at which time the margin on those loans increases by 0.50% for the relevant period. The facility is secured by substantially all assets of BioCryst and its subsidiaries and includes customary covenants and events of default, plus prepayment premiums that step down from 3.00% to 0% over four years.

On the same date, BioCryst completed its merger with Astria Therapeutics, with Astria becoming a wholly owned subsidiary. Each share of Astria common stock was converted into the right to receive 0.59 BioCryst share plus $8.55 in cash, subject to standard adjustments, combining the two companies’ businesses.

BioCryst Pharmaceuticals reported preliminary, unaudited full-year 2025 net revenue from its hereditary angioedema drug ORLADEYO of $601 million, which the company highlighted as a 37 percent year-over-year increase and above its prior guidance range. The company also discussed non-GAAP views of ORLADEYO sales that exclude European revenue to show comparable growth, noting 36 percent growth for the fourth quarter of 2025 and 43 percent growth for the full year 2025 on this basis. In the same update, BioCryst provided guidance for 2026 ORLADEYO net revenue, total revenue, and operating expenses, and reminded investors of its presentation at the J.P. Morgan Healthcare Conference.

BioCryst Pharmaceuticals, Inc. is increasing the U.S. wholesale acquisition cost of its hereditary angioedema treatment ORLADEYO (berotralstat) effective January 9, 2026. The price is rising from $44,484.33 to $48,487.92 per 28-day pack of either the 150mg or 110mg capsules. This change applies to the wholesale acquisition cost, which is a list price used in transactions between the company and its buyers in the United States.

BioCryst Pharmaceuticals reports that the U.S. Food and Drug Administration has approved its new drug application for an oral pellet formulation of once-daily ORLADEYO (berotralstat). The approval covers use of this oral pellet formulation as prophylactic therapy in pediatric patients with hereditary angioedema aged 2 to <12 years.

The company has furnished a press release with additional details about this FDA approval as an exhibit to this report.

BioCryst Pharmaceuticals furnished a press release announcing recent corporate developments and financial results for the third quarter ended September 30, 2025. The company also referenced a conference call and webcast to discuss these updates.

The press release is attached as Exhibit 99.1. The information was furnished, not filed, which means it is not subject to Section 18 liability and is not incorporated into other filings unless specifically referenced.

BioCryst Pharmaceuticals (BCRX) agreed to acquire Astria Therapeutics via a cash-and-stock merger. Each Astria share will be exchanged for $8.55 in cash plus 0.59 of a BioCryst common share, with a cap that limits total new BioCryst shares to 19.9% of pre-close shares; if that cap is reached, the share portion decreases and the cash portion increases by the same value.

Closing is subject to Astria stockholder approval, HSR clearance, SEC effectiveness of a Form S-4 registering the BioCryst shares, Nasdaq listing approval for the new shares, and other customary conditions. The companies anticipate closing in the first quarter of 2026. Under specified circumstances, Astria would owe BioCryst a $32,250,000 termination fee.

BioCryst obtained a $550,000,000 senior secured debt commitment from Blackstone, including a $350,000,000 initial term loan and a $50,000,000 committed delayed draw, to help fund the consideration and related fees at closing. BioCryst also fully repaid and terminated its prior BioPharma Credit loan. Subject to the merger’s effective time, Astria CEO Jill C. Milne, Ph.D. is expected to join the BioCryst board, with an initial equity grant valued at $500,000.

BioCryst Pharmaceuticals, Inc. filed a Form 8-K reporting the consummation of a Transaction and furnishing a set of related agreements dated October 1, 2025. The filing lists six exhibits between the company and BioCryst Ireland: an Amended and Restated IP Licence Agreement, a Supply Agreement, a Global Brand and Support Agreement, a Transition Services Agreement, a Trademark License Agreement, and a Press Release regarding the Transaction. The filing states that schedules and exhibits to those agreements were omitted from the public filing under Item 601(a)(5) of Regulation S-K and are available to the SEC on request.

BioCryst Pharmaceuticals announced that Dr. Helen Thackray will resign as Chief Research and Development Officer effective September 1, 2025. She said she will pursue new opportunities and cited no disagreement with the Board. The Company and Dr. Thackray entered a Separation Agreement providing one year of continued base salary, payment of her 2025 annual incentive plan bonus based on actual performance plus payment of her target 2025 bonus, up to 12 months of company-paid group health continuation, up to six months of outplacement services, and accelerated vesting of equity awards scheduled to vest in 2026. The Compensation Committee also approved a Consulting Agreement through December 31, 2025 under which she will provide transition services for a $12,500 monthly fee, with continued vesting of equity awards during the consulting period and six-month post-consulting option exercisability. These arrangements are intended to support an orderly transition while creating near-term compensation and equity vesting obligations.

BioCryst Pharmaceuticals (Nasdaq: BCRX) filed an 8-K announcing a planned CEO transition. Incumbent President & CEO Jon Stonehouse will retire on 31 Dec 2025 after 17 years at the helm; he reports no disagreements and will stay on the board. He retains eligibility for his 2025 bonus and up to 18 months of subsidised health coverage.

The board named current Chief Commercial Officer Charlie Gayer (age 54) as President effective 1 Aug 2025 and as CEO effective 1 Jan 2026. Compensation terms include:

• 2025 base salary raised to $675k; annual incentive target blended at 70-75% of salary.
• From 2026: base salary $775k; AIP target set at 85% of salary.
• Severance (without cause / post-change-of-control): two years of salary, 2× target bonus over two years, and up to 12 months of subsidised health coverage.

The board will expand from nine to ten directors and elect Gayer to the new seat beginning 1 Jan 2026 (term ends 2028). No related-party transactions or disagreements were disclosed, and Gayer will initially serve on no board committees.

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) filed an 8-K announcing a key leadership change. Effective 7 July 2025, the Board appointed Babar Ghias (46) as Chief Financial Officer, Principal Accounting Officer and Head of Corporate Development. Mr. Ghias brings two decades of healthcare and life-sciences experience, including CFO roles at AvenCell Therapeutics and Marathon Pharmaceuticals and M&A advisory work at Credit Suisse.

Compensation package includes: (i) base salary of $560,000; (ii) annual incentive target equal to 70 % of salary (full-year eligible for 2025); (iii) a $160,000 one-time cash bonus payable within 30 days; and (iv) Inducement Grants on 31 July 2025 of 147,000 RSUs and 305,000 stock options, vesting in four equal annual tranches from the first anniversary of grant.

The filing states Mr. Ghias has no related-party transactions, no special arrangements leading to his appointment, and no family relationships with existing directors or officers. A press release (Ex. 99.1) concurrently discloses the hire.

Investor take-away: While the event does not change current financial guidance, BioCryst strengthens its executive bench with a CFO possessing commercialisation and deal-making expertise that could support future capital strategy and business development.

BioCryst Pharmaceuticals (Nasdaq:BCRX) filed an 8-K announcing it has signed a definitive Stock Purchase Agreement dated June 27 2025 to sell 100% of the equity of BioCryst Ireland Ltd. and its subsidiaries to Neopharmed Gentili S.p.A.

No purchase price was disclosed, and closing is subject to customary regulatory approvals, financing by the buyer and other conditions. The company warns of possible business disruption, transaction costs and relationship changes during the interim period.

The press release is furnished as Exhibit 99.1; no pro-forma financials were included. Management makes forward-looking statements regarding timing, benefits and risks of the divestiture.

BioCryst Pharmaceuticals (NASDAQ:BCRX) announced that the FDA has extended the PDUFA goal date for their NDA regarding ORLADEYO oral granules for pediatric HAE patients aged 2-11 years. The 3-month extension moves the target action date to December 12, 2025. The extension was triggered by the company's submission of additional final reports and formulation data, which the FDA classified as a major amendment requiring full review.

The delay affects the potential expansion of ORLADEYO, currently approved for other age groups, into the pediatric hereditary angioedema market segment. The FDA requires additional time to review the supplementary data for safety and efficacy in young patients.